Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy.
An unusual case of bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during treatment with granulocyte colony-stimulating factor (G-CSF) is reported. The possible relationship between G-CSF therapy and pyoderma gangrenosum, as well as the beneficial effect of cyclosporin A therapy, is discussed.
Lewerin
C
C
Department of Medicine, Ostra University Hospital, Sweden.
Mobacken
H
H
Nilsson-Ehle
H
H
Swolin
B
B
D000368:Aged; D016572:Cyclosporine / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy*; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000188:drug therapy*; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D016179:Granulocyte Colony-Stimulating Factor; D016572:Cyclosporine